News | October 08, 2024
AstraZeneca, CSPC Pharmaceutical agree for a pre-clinical novel lipid-lowering therapy
CSPC will receive an upfront payment of $100 million from AstraZeneca
CSPC will receive an upfront payment of $100 million from AstraZeneca
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
This is used to treat central diabetes insipidus and bedwetting
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
Subscribe To Our Newsletter & Stay Updated
